Syngene share price today: April 2026 depth, FY25 update

Syngene share price on 29 April 2026

Syngene International Ltd (SYNGENE) was quoted at ₹433.40 on 29 April 2026, as per the provided market snapshot. The price level is presented alongside BSE market depth data for the same date. The update also states the stock was 40.69% away from its 52-week high. That gap signals the counter was trading well below its peak, although the snapshot does not specify the exact 52-week high value. The same source flags that intraday prices can change due to market conditions. A short-term performance datapoint in the text shows a past 1-week return of -0.18%. Taken together, the inputs frame the day’s quote as part of a softer recent trend.

BSE market depth: what the order book showed

The BSE market depth table lists the top five buy and sell levels visible at the time of capture. On the bid side, the highest buy price listed was ₹430.30 for 3 shares. Additional bids were shown at ₹430.20 (5 shares) and ₹430.00 (60 shares), followed by ₹429.65 (213 shares). A lower bid was shown at ₹425.00 for 1 share. On the offer side, the lowest sell price listed was ₹432.30 for 100 shares. Higher offers included ₹433.40 (463 shares) and ₹437.50 (75 shares), with ₹442.50 (48 shares) and ₹444.40 (1 share) further up. While this is only a partial book, it provides a view of where immediate demand and supply were stacked.

Quarter cues: June 2025 sales growth

The text cites a quarterly sales comparison for the quarter ended June 2025. Sales rose 10.74% to ₹874.50 crore versus ₹789.70 crore in the quarter ended June 2024. This indicates double-digit growth on a year-on-year basis for that quarter. The numbers are presented as sales rather than profit metrics, so they mainly reflect demand and execution. No segment split is provided in the excerpt. The data also does not specify whether the figure is standalone or consolidated. Still, it anchors a clear year-on-year growth rate for that period.

Q4 FY25: EBITDA up, margin slightly lower

For Q4 ended March 2025, reported EBITDA rose 9% year-on-year to ₹363 crore. The EBITDA margin stood at 35% in Q4FY25, compared with 35.7% in Q4FY24. That points to a modest margin contraction even as operating profit increased. The excerpt does not provide the full income statement, but it highlights the two key profitability markers investors track. The numbers suggest profitability improved in absolute terms, but costs or mix may have limited margin expansion. The market reaction context is not fully detailed in the data provided. However, the margin comparison is explicit and measurable.

Full-year FY25: revenue growth, profit decline

For the full year ended March 2025, net profit declined 2.71% to ₹496.20 crore. Over the same period, net sales rose 4.41% to ₹3,642.40 crore compared with the year ended March 2024. This combination implies growth in the top line without a matching increase in bottom line. The excerpt does not specify what drove the profit decline. It also does not list exceptional items for the full year. Even so, the stated percentages and absolute values establish the direction of change. For investors, this mix often shifts attention to margins, cost controls, and near-term guidance.

Another quarterly reference: crossing ₹1,000 crore revenue

The provided text also states that Syngene ended the year on “a solid note” with reported revenue from operations of ₹1,018 crore. It adds this was an increase of 11% year-on-year and 8% sequentially. The same passage notes quarterly operating revenue crossed the ₹1,000 crore threshold for the first time. It further mentions operating EBITDA was up 8% year-on-year and 21% sequentially, but the absolute EBITDA number is not included in the excerpt. On profit, the text says profit-after-tax and exceptional items for the quarter was down 3% year-on-year to ₹183 crore. It also repeats that PAT before exceptional items decreased 3% year-on-year to ₹183 crore, and that sequentially it grew 8% over the third quarter. Since the excerpt is incomplete in places, only the stated figures are cited here.

Brokerage view in the text: Macquarie’s target and rating

A brokerage note in the provided material says Macquarie reiterated an “outperform” rating on Syngene International. The note sets a price target of ₹835 per share. It describes this as implying roughly 27% to about 28% upside from the previous close (both figures appear in the provided text). The rationale mentioned includes an improved risk-reward profile, expectations of better core fundamentals, and an “attractive” valuation. The excerpt also references Syngene’s contract research (CRO) and contract development (CDO) businesses as areas of focus. No detailed model assumptions are included in the snippet. The rating and target are therefore the key actionable disclosures available.

Market impact: what the numbers imply for investors

The day’s quote of ₹433.40 and the “40.69% away from 52-week high” statement together indicate the stock was well below peak levels. The market depth levels show near-term supply visible above ₹432.30, including an offer at ₹433.40 for 463 shares. On fundamentals, FY25 net sales growth of 4.41% contrasted with a 2.71% net profit decline suggests margin or cost pressures during the year. Q4FY25 EBITDA at ₹363 crore and a 35% margin provide a reference point for profitability tracking. The June 2025 sales growth of 10.74% points to a stronger top-line pace in that quarter comparison. The quarterly ₹1,018 crore revenue reference and the “first time above ₹1,000 crore” comment highlight a scale milestone. Macquarie’s ₹835 target indicates that at least one brokerage sees significant upside, though the excerpt does not reconcile this with the ₹433.40 spot quote shown earlier.

Analysis: why this mix of signals matters

The snapshot combines three decision inputs investors typically weigh: price action, order-book cues, and earnings trajectory. A stock trading far below its 52-week high can attract value interest, but it can also reflect earnings disappointments or guidance concerns not fully captured here. The FY25 pattern of rising revenue but lower profit makes margins a central monitorable variable, especially with Q4 margin slipping from 35.7% to 35%. The quarter sales growth figure of ₹874.50 crore (June 2025) adds context that growth was stronger in at least one recent quarter comparison. Meanwhile, Macquarie’s reiterated “outperform” rating and ₹835 target show that broker conviction exists in the dataset provided. Still, the excerpt contains multiple price references across different contexts, so readers should treat each number as tied to its stated date and source. From a market-structure angle, the market depth table provides only a partial view, but it helps frame immediate liquidity around the quoted prices.

Conclusion

Syngene’s ₹433.40 quote on 29 April 2026 comes alongside visible sell orders near ₹432.30 to ₹444.40 and a stated 40.69% gap to the 52-week high. On fundamentals, FY25 net sales rose to ₹3,642.40 crore while net profit slipped to ₹496.20 crore, and Q4 EBITDA increased to ₹363 crore with a slightly lower margin. The provided material also highlights a quarterly revenue milestone of ₹1,018 crore and a PAT figure of ₹183 crore for that quarter reference. Macquarie’s reiterated “outperform” rating with a ₹835 target underscores how brokerage views can diverge from spot trading levels shown in the same dataset. Investors tracking the stock will likely continue to map price moves against quarterly execution and margins as new updates arrive. Any further clarity would depend on the company’s subsequent results and guidance disclosures referenced by market participants.